| Literature DB >> 28793908 |
Leema George1, Ankita Mitra1, Tania A Thimraj1, Martin Irmler2, Sangeetha Vishweswaraiah1, Lars Lunding3, Dorothea Hühn4,5, Alicia Madurga6, Johannes Beckers2,7,8, Heinz Fehrenbach9, Swapna Upadhyay10,11, Holger Schulz12,13, George D Leikauf14, Koustav Ganguly15,16,17,18.
Abstract
BACKGROUND: Failure to attain peak lung function by early adulthood is a risk factor for chronic lung diseases. Previously, we reported that C3H/HeJ mice have about twice total lung capacity (TLC) compared to JF1/MsJ mice. We identified seven lung function quantitative trait loci (QTL: Lfnq1-Lfnq7) in backcross/intercross mice derived from these inbred strains. We further demonstrated, superoxide dismutase 3, extracellular (Sod3), Kit oncogene (Kit) and secreted phosphoprotein 1 (Spp1) located on these Lfnqs as lung function determinants. Emanating from the concept of early origin of lung disease, we sought to identify novel candidate genes for pulmonary function by investigating lung transcriptome in C3H/HeJ and JF1/MsJ mice at the completion of embryonic development, bulk alveolar formation and maturity.Entities:
Keywords: Asthma; Chronic obstructive pulmonary disease; Lung development; Transcriptomics; WNT Signaling
Mesh:
Year: 2017 PMID: 28793908 PMCID: PMC5551015 DOI: 10.1186/s12931-017-0629-3
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Morphometric evaluation of C3H/HeJ and JF1/MsJ mouse lung
| Morphometric Parameters | C3H/HeJ | JF1/MsJ |
| C3H/HeJ | JF1/MsJ |
|
|---|---|---|---|---|---|---|
| Number of mice | MALE: | FEMALE: | ||||
| Age (weeks) | 13 | 12–14 | 13 | 12–14 | ||
| Fixed lung volume (μl) | 1092 ± 123 | 735 ± 71 | 0.001 | 987 ± 54 | 667 ± 23 | 0.001 |
| Mean chord length (Lcm) (μm) | 74.3 ± 9.9 | 48.5 ± 5.5 | 0.002 | 69.2 ± 14.8 | 47.3 ± 2.0 | 0.011 |
| Mean alveolar volume (103/μm3) | 61.1 ± 7.9 | 40.8 ± 5.9 | 0.01 | 71.5 ± 11.4 | 42.3 ± 7.0 | 0.007 |
| Alveolar number density (106/cm3 parenchyma) | 10.2 ± 1.1 | 14.7 ± 2.0 | 0.005 | 8.8 ± 1.5 | 14.5 ± 2.2 | 0.001 |
| Alveolar septum width (μm) | 0.72 ± 0.07 | 0.66 ± 0.08 | ns | 0.82 ± 0.14 | 0.63 ± 0.11 | 0.005 |
| Total number of alveoli (106/both lungs) | 9.2 ± 1.1 | 8.9 ± 1.7 | ns | 6.9 ± 1.4 | 8.2 ± 1.6 | ns |
| Total alveolar surface area (cm2) | 952 ± 88 | 957 ± 125 | ns | 847 ± 70 | 906 ± 102 | ns |
| Elastin - collagen ratio | 1.40 ± 0.3 | 1.95 ± 0.3 | 0.004 | 1.83 ± 0.3 | 2.12 ± 0.2 | 0.035 |
| Absolute volumes | ||||||
| Parenchymal volume (mm3) | 933 ± 112 | 629 ± 72 | 0.001 | 849 ± 71 | 571 ± 28 | 0.001 |
| Non-parenchymal volume (mm3) | 145 ± 33 | 98 ± 23 | 0.002 | 126 ± 22 | 78 ± 11 | 0.003 |
| Alveolar airspace volume (mm3) | 574 ± 73 | 377 ± 53 | 0.001 | 514 ± 41 | 340 ± 21 | 0.001 |
| Alveolar duct airspace volume (mm3) | 261 ± 32 | 167 ± 26 | 0.041 | 237 ± 28 | 155 ± 15 | ns |
| Alveolar septal volume (mm3) | 69 ± 12 | 63 ± 5 | ns | 69 ± 11 | 58 ± 5 | ns |
| Total alveolar surface density (μm2/μm3) | 0.10 ± 0.01 | 0.15 ± 0.01 | ns | 0.11 ± 0.01 | 0.16 ± 0.01 | ns |
| Alveolar epithelial type I cells (mm3) | 19.5 ± 3.3 | 19.2 ± 3.2 | ns | 20,8 ± 4.02 | 15.5 ± 3.45 | ns |
| Alveolar epithelial type II cells (mm3) | 6.0 ± 2.8 | 7.8 ± 4.6 | ns | 4.3 ± 1.5 | 6.5 ± 2.7 | ns |
| Capillary endothelial cells (mm3) | 16.3 ± 3.7 | 13.6 ± 1.4 | ns | 15.8 ± 1.9 | 11.8 ± 2.5 | ns |
| Interstitial tissue (mm3) | 22.7 ± 5.3 | 17.5 ± 2.1 | ns | 22.5 ± 4.5 | 19.3 ± 6.1 | ns |
| Total alveolar surface area (cm2) | 952 ± 88 | 957 ± 125 | ns | 847 ± 70 | 906 ± 102 | ns |
| Volume densities | ||||||
| Alveolar epithelial type I cells (mm3/mm3) | 28.2 ± 1.5 | 30.5 ± 4.2 | ns | 30.2 ± 2.1 | 27.23 ± 2.4 | ns |
| Alveolar epithelial type II cells (mm3/mm3) | 9.0 ± 4.2 | 12.5 ± 6.7 | ns | 6.3 ± 3.4 | 10.9 ± 4.0 | ns |
| Capillary endothelial cells (mm3/mm3) | 23.3 ± 2.3 | 21.7 ± 3.1 | ns | 22.8 ± 1.9 | 21.2 ± 2.5 | ns |
| Interstitial tissue (mm3/mm3) | 32.9 ± 3.7 | 28.2 ± 2.6 | ns | 32.5 ± 3.0 | 33.2 ± 3.1 | ns |
| Collagen (mm3/mm3) | 2.78 ± 0.49 | 2.63 ± 0.51 | ns | 3.02 ± 0.62 | 2.42 ± 0.41 | ns |
| Elastin (mm3/mm3) | 3.87 ± 1.23 | 5.08 ± 1.06 | ns | 5.3 ± 1.55 | 5.08 ± 0.72 | ns |
| Lung function |
|
| n-3 | n-3 | ||
| Total Lung capacity (TLC) (μl) | 1425 ± 164 | 750 ± 50 | <0.05 | 1467 ± 125 | 800 ± 82 | <0.05 |
| Compliance air (μl/cm H20) | 143 ± 5 | 36 ± 7 | <0.05 | 130 ± 6 | 34 ± 6 | <0.05 |
| Compliance saline (μl/cm H20) | 306 ± 46 | 96 ± 13 | <0.05 | 296 ± 37 | 107 ± 20 | <0.05 |
| Specific compliance saline (μl/cm H20) | 214 ± 15 | 128 ± 5 | <0.05 | 202 ± 9 | 134 ± 23 | <0.05 |
| Compliance saline/Compliance air | 2.2 ± 0.4 | 2.7 ± 0.1 | <0.05 | 2.3 ± 0.2 | 3.2 ± 0.9 | <0.05 |
ns not significant
Values are mean ± S.D. Significant difference between sex-matched mouse strains was determined by ANOVA
Extracellular region is an enriched gene ontology category (GO: 0005576) associated with the significantly decreased transcripts in JF1/MsJ vs C3H/HeJ mouse lung at embryonic day 18 (E18) and postnatal day 70 (P70)
| Gene | Gene symbol | Entrez ID | Fold Difference |
|---|---|---|---|
| E18 decreased transcripts of GO term extracellular region; Enrichment Score = 2.83; | |||
| Chemokine (C-X-C motif) ligand 15 |
| 20,309 | −14.6 |
| Hemolytic complement |
| 15,139 | −8.61 |
| Kallikrein 1-related peptidase b21 |
| 16,616 | −8.25 |
| Surfactant associated protein A1 |
| 20,387 | −3.80 |
| Collagen, type XXVIII, alpha 1 |
| 213,945 | −3.15 |
| Paraoxonase 3 |
| 269,823 | −2.96 |
| Ceruloplasmin |
| 12,870 | −2.95 |
| Neuron-derived neurotrophic factor |
| 68,169 | −2.41 |
| Fibroblast growth factor 1 |
| 14,164 | −2.21 |
| EGF-like, fibronectin type III and laminin G domains |
| 268,780 | −2.13 |
| Transferrin |
| 22,041 | −2.12 |
| Interleukin 33 |
| 77,125 | −2.04 |
| P70 decreased transcripts of GO term extracellular region; Enrichment Score = 4.18; | |||
| Hemolytic complement |
| 15,139 | −27.88 |
| Chitinase 3-like 3 |
| 12,655 | −15.93 |
| Kallikrein 1-related peptidase b21 |
| 16,616 | −11.92 |
| Hepcidin antimicrobial peptide |
| 84,506 | −4.87 |
| Chemokine (C-C motif) ligand 6 |
| 20,305 | −3.92 |
| Matrix metallopeptidase 3 |
| 17,392 | −3.62 |
| Insulin-like growth factor binding protein 6 |
| 16,012 | −2.83 |
| Collagen, type XXVIII, alpha 1 |
| 213,945 | −2.76 |
| Angiopoietin-like 7 |
| 654,812 | −2.72 |
| Leptin receptor |
| 16,847 | −2.28 |
| Chitinase, acidic |
| 81,600 | −2.26 |
| Oxidized low density lipoprotein (lectin-like) receptor 1 |
| 108,078 | −2.21 |
| Coagulation factor VII |
| 14,068 | −2.18 |
| Paraoxonase 3 |
| 269,823 | −2.18 |
| Plasminogen activator, tissue |
| 18,791 | −2.10 |
| Secreted Ly6/Plaur domain containing 1 |
| 57,277 | −2.02 |
Values are mean fold difference of (JF1/MsJ)/(C3H/HeJ) for lung transcript levels (cut off for fold change ≥2 fold; false discovery rate 0.10)
Lung transcripts (34 genes) consistently increased (12) or decreased (22) across embryonic stage 18 (E18), postnatal stage (P) 28 and P70 in JF1/MsJ (JF1) mice compared to C3H/HeJ (C3H)
| Gene Name | Gene symbol | Entrez ID | Probeset | Fold Difference | ||
|---|---|---|---|---|---|---|
| E18 | P28 | P70 | ||||
| Glutaredoxin 3 |
| 30,926 | 6,923,313 | 12.22 | 6.08 | 3.27 |
| RIKEN cDNA G730007D18 gene |
| 100,038,502 | 7,006,004 | 3.66 | 2.87 | 2.41 |
| Holliday junction recognition protein |
| 381,280 | 6,760,490 | 3.58 | 2.09 | 2.20 |
| Synaptonemal complex central element protein 1 |
| 74,075 | 6,972,143 | 3.00 | 2.06 | 2.13 |
| Predicted gene 14,403 |
| 433,520 | 6,883,977 | 2.98 | 2.79 | 2.68 |
| RIKEN cDNA 2,610,028 J07 gene |
| 71,813 | 6,859,453 | 2.94 | 2.74 | 2.82 |
| Microspherule protein 1 |
| 51,812 | 6,918,337 | 2.62 | 2.03 | 2.30 |
| RIKEN cDNA 2610507I01 gene |
| 72,203 | 6,788,659 | 2.60 | 5.35 | 3.74 |
| Olfactory receptor 1061 |
| 259,022 | 6,888,451 | 2.51 | 2.81 | 3.77 |
| Olfactory receptor 170 |
| 258,959 | 6,844,403 | 2.47 | 4.67 | 3.43 |
| Uncharacterized protein C130090J04 |
| 328,049 | 6,860,959 | 2.36 | 2.12 | 2.20 |
| RIKEN cDNA 6,330,403 K07 gene |
| 103,712 | 6,789,483 | 2.32 | 7.15 | 6.56 |
| Glucagon-like peptide 1 receptor |
| 14,652 | 6,849,762 | −2.02 | −2.33 | −2.06 |
| Solute carrier family 39 (metal ion transporter), member 8 |
| 67,547 | 6,901,634 | −2.07 | −2.43 | −2.51 |
| Sodium channel, voltage-gated, type III, alpha |
| 20,269 | 6,887,324 | −2.08 | −5.31 | −4.49 |
| Sterile alpha motif domain containing 9-like |
| 209,086 | 6,951,281 | −2.08 | −2.74 | −3.05 |
| Interferon-induced protein 44 |
| 99,899 | 6,910,592 | −2.10 | −2.86 | −2.19 |
| Transmembrane protein 181A |
| 77,106 | 6,848,520 | −2.13 | −2.60 | −2.40 |
| NME/NM23 family member 7 |
| 171,567 | 6,754,701 | −2.13 | −2.49 | −2.70 |
| Protein phosphatase 1, regulatory (inhibitor) subunit 3A |
| 140,491 | 6,951,783 | −2.19 | −2.10 | −3.06 |
| Megalencephalic leukoencephalopathy with subcortical cysts 1 homolog (human) |
| 170,790 | 6,837,773 | −2.24 | −2.78 | −3.13 |
| Cytochrome P450, family 2, subfamily J, polypeptide 6 |
| 13,110 | 6,923,520 | −2.29 | −2.27 | −2.39 |
| RIKEN cDNA A330076H08 gene |
| 320,026 | 6,967,799 | −2.35 | −2.53 | −2.06 |
| Aminolevulinate, delta-, dehydratase |
| 17,025 | 6,922,241 | −2.82 | −2.54 | −2.67 |
| RIKEN cDNA D230046O15 gene |
| 106,824 | 6,856,766 | −3.00 | −3.63 | −2.54 |
| Nuclear paraspeckle assembly transcript 1 (non-protein coding) |
| 66,961 | 6,867,774 | −3.54 | −3.45 | −2.70 |
| Surfactant associated 2 |
| 433,102 | 6,850,183 | −4.02 | −2.19 | −2.23 |
| Transmembrane protein 181A |
| 77,106 | 6,812,918 | −4.26 | −4.08 | −3.40 |
| RIKEN cDNA B930063I24 gene |
| 319,330 | 6,756,745 | −5.06 | −4.33 | −6.19 |
| G protein-coupled receptor 137B |
| 83,924 | 7,003,081 | −5.39 | −5.38 | −3.06 |
| Zinc finger, X-linked, duplicated B |
| 668,166 | 7,021,109 | −6.18 | −7.68 | −7.23 |
| Kallikrein 1-related peptidase B21 |
| 16,616 | 6,960,239 | −8.25 | −19.87 | −11.92 |
| Hemolytic complement |
| 15,139 | 6,886,022 | −8.61 | −32.16 | −27.88 |
| RIKEN cDNA A730017L22 gene |
| 613,258 | 6,890,967 | −13.13 | −15.62 | −14.60 |
Values are mean fold change for transcripts (cut off for fold change ≥2 fold; false discovery rate = 0.10
Fig. 1Comparative expression of lung Wnt inhibitor factor 1 (Wif1) and frizzled homolog 6 (Fzd6) and chitinase 3 like 3 (CHIL3) in JF1/MsJ and C3H/HeJ mice. a Expression of lung Wif1 mRNA in JF1/Msf was increased compared with C3H/HeJ mice at postnatal (P) days P28 and P70. b Expression of lung Fzd6 mRNA in JF1/Msf was decreased compared to C3H/HeJ mice at P28 and P70. Quantitative real-time polymerase chain reaction was performed, and the comparative cycle number threshold (CT) method (ΔΔCT) was used [ΔCT = CT (gene)-CT(Actb)]. Data are presented as expression relative to time-matched C3H/HeJ level (means ± SE; n = 5 mice/strain/stage). *Significantly different from C3H/HeJ (ANOVA followed by all pairwise multiple-comparison procedures with Holm-Sidak method, P < 0.05). c Western blot analysis of CHIL3 from total lung homogenate of P28 C3H/HeJ and JF1/MsJ mice (n = 3 mice/strain; female). Lung transcript expression showed > 15 fold decreased Chil3 expression in Jf1/MsJ compared to C3H/HeJ. β-actin (ACTB) was used as the control. Photograph is representative of at least three observations
Fig. 2Localization of Wnt inhibitor factor 1 (WIF1) protein in the lungs of four weeks old female C3H/HeJ and JF1/MsJ mice (n = 5). Increased WIF1 immunostaining was detected in the b, e airway epithelium and h alveolar type I and type II cells of JF1/MsJ lungs compared with those of c, f, i C3H/HeJ mice. a, d, g Sections incubated phosphate-buffered saline (PBS control) without primary antisera
Fig. 3Localization of follistatin (FST) protein in the lungs of four weeks old female C3H/HeJ and JF1/MsJ mice (n = 5). Increased of FST immunostaining was detected in the b, e airways and h alveolar type I and type II cells of JF1/MsJ lungs compared with those of c, f, i C3H/HeJ mice. a, d, g Sections incubated phosphate-buffered saline (PBS control) without primary antisera
Fig. 4Localization of frizzled homolog 6 (FZD6) protein in the lungs of four weeks old female C3H/HeJ and JF1/MsJ mice (n = 5). Decreased FZD6 immunostaining was detected in the b, e airways and h alveolar type I and type II cells of JF1/MsJ lungs compared with those of c, f, i C3H/HeJ mice. a, d, g Sections incubated phosphate-buffered saline (PBS control) without primary antisera
Candidate genes for total lung capacity (TLC) in mice identified through the expression quantitative trait loci (e-QTL) strategy comparing C3H/HeJ (C3H) and JF1/MsJ (JF1). [cut off for fold change ≥2.0 fold at least in one stage among embryonic stage 18, postnatal stage (P) 28 and P70; false discovery rate = 0.10]
| Trait | QTL Region | QTL Location (Basepair) | Gene Description | Gene symbol/location (basepair) | EntrezID | Fold Difference | ||
|---|---|---|---|---|---|---|---|---|
| E18 | P28 | P70 | ||||||
| Lfnq3 Chromosome: 15 | ||||||||
| TLC, TLC/Bw |
| 40,313,626–72,500,731 | Leucine rich repeat containing 6 (testis) |
| 54,562 | −2.03 | ns | ns |
| Lfnq4 Chromosome: 17 | ||||||||
| TLC |
| 10,987,597–39,053,168 | Radial spoke head 1 homolog (Chlamydomonas) |
| 22,092 | ns | 2.81 | 2.63 |
| Formyl peptide receptor 1 |
| 14,293 | −2.05 | −1.75 | −2.26 | |||
| ATP-binding cassette, sub-family G (WHITE), member 1 |
| 11,307 | ns | −1.76 | −2.44 | |||
| Surfactant associated 2 |
| 433,102 | −4.02 | −2.19 | −2.23 | |||
| Histocompatibility 2, class II antigen E beta |
| 14,969 | ns | −2.23 | −2.21 | |||
| Histocompatibility 2, D region locus 1 |
| 14,964 | ns | 2.21 | 2.11 | |||
| Histocompatibility 2, Q region locus 4 |
| 15,015 | −1.52 | −3.19 | −2.86 | |||
| Gamma-aminobutyric acid (GABA) B receptor, 1 |
| 54,393 | −2.20 | −1.68 | −1.62 | |||
ns not significant